Dyadic International (DYAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Jun, 2026Executive summary
Received notification from Nasdaq regarding potential delisting due to failure to meet minimum bid price and continued listing standards as of June 18, 2026.
Company failed to regain compliance with the $1.00 minimum bid price and did not meet the $5 million shareholders' equity requirement by June 17, 2026.
Additional deficiencies include not meeting $2.5 million in shareholders' equity, $35 million market value, or $500,000 net income from continuing operations.
Plans to request a hearing before an independent Nasdaq panel, which will temporarily stay any suspension or delisting action.
Maximum extension for compliance runs through December 15, 2026, but there is no assurance of regaining compliance or avoiding delisting.
Risk oversight and compliance
Forward-looking statements highlight risks such as net losses, regulatory acceptance, commercialization challenges, competition, and capital needs.
Risks also include reliance on third parties, government regulations, intellectual property, and ability to comply with Nasdaq standards.
Reference to detailed risk factors in annual and quarterly SEC filings.
Shareholder rights and capital structure
Failure to comply with Nasdaq listing standards may adversely affect liquidity, market price, and ability to raise capital.
Delisting could impact the company's ability to operate as a going concern.
Latest events from Dyadic International
- Scalable, animal-free protein platforms deliver rapid, high-yield solutions for global biologics markets.DYAI
Corporate presentation - Flat Q2 revenue, higher costs, and cash burn widened losses and increased going concern risk.DYAI
Q2 2026 - Commercialization accelerates with new product launches and partnerships, targeting rapid revenue growth.DYAI
IAccess Alpha Virtual MicroCap Conference - All proposals passed, with strategic focus on commercial growth and Nasdaq compliance efforts.DYAI
AGM 2026 - Commercial stage reached with six product launches, global distribution, and early recurring revenues.DYAI
Lytham Partners Spring 2026 Investor Conference - Shifted to commercial focus with new product launches, wider net loss, and strong liquidity.DYAI
Q3 2025 - Q2 2025 revenue surged and net loss narrowed as commercial focus and new funding accelerated growth.DYAI
Q2 2025 - Q3 2024 revenue rose 393% to $1.96M, net loss narrowed, and cash reached $10M.DYAI
Q3 2024 - Revenue up 18% on grants; product launches and strong liquidity expected in 2025.DYAI
Q1 2025